Aytu Biopharma (AYTU) Payables (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Payables data on file, last reported at $13.2 million in Q1 2026.

• On a quarterly basis, Payables rose 9.74% year-over-year to $13.2 million in Q1 2026; TTM through Mar 2026 was $13.2 million, a 9.74% increase from a year earlier, with the FY2025 full-year figure at $10.6 million, down 16.59% from the prior year.
• Payables for Q1 2026 stood at $13.2 million, down from $14.3 million in the prior quarter.
• Over the last five years, Payables for AYTU reached as high as $17.8 million in Q3 2024 and fell as low as $1.2 million in Q3 2023.
• Historically, Payables has averaged $11.5 million across 5 years, with a median of $12.3 million in 2025.
• Across the five-year window, Payables plunged 80.2% in 2022 and soared 1363.62% in 2024, its largest moves.
• Year by year, Payables stood at $7.4 million in 2022, then surged by 54.79% to $11.5 million in 2023, then jumped by 36.63% to $15.7 million in 2024, then slipped by 9.24% to $14.3 million in 2025, then decreased by 7.33% to $13.2 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $13.2 million in Q1 2026, $14.3 million in Q4 2025, and $12.3 million in Q3 2025.